Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age

Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements

Beat AML master trial update: A clinical trial for acute myeloid leukaemia

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone

Bladder cancer updates from the second half of 2024

SIOG 2024: Updates in haematology

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients

Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM

Understanding the remaining unmet needs in a post ASCT NDMM setting

Approaches to risk stratification in high risk myeloma

Tailored to fit: New approaches in transplant-ineligible NDMM

Advancements in minimal residual disease detection in myeloma